Danish pharmaceutical company Lundbeck has signed a definitive agreement to acquire all outstanding...
- Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
- Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
- Boehringer acquires AMAL Therapeutics for $366m
- Pfizer acquires rare disease biotech Therachon for $340m
- GSK and University of California team up on CRISPR research
Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals
Danish pharmaceutical company Lundbeck has signed a definitive agreement to acquire all outstanding shares of US-based Alder BioPharmaceuticals for a maximum consideration of $1.95bn.
Amplyx licences Phase II anti-viral candidate from Novartis
US-based Amplyx Pharmaceuticals has obtained exclusive global rights from Novartis to a monoclonal antibody, MAU868, to prevent and treat BK viral disease.
Inotrem secures funds to develop septic shock treatment
Biotechnology company Inotrem has secured series B funding to develop immunotherapy candidates targeting septic shock and chronic inflammatory conditions.
Atomwise inks four new deals for AI-based drug discovery
US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI) technology for the discovery of new drugs across various therapeutic areas.
GSK to buy Sitari Pharmaceuticals from Avalon Ventures
UK-based pharmaceutical company GlaxoSmithKline (GSK) has signed a definitive agreement with Avalon Ventures to acquire Sitari Pharmaceuticals for an undisclosed amount.
Sanofi to pay Lexicon $260m over terminated Zynquista alliance
Lexicon Pharmaceuticals has announced a $260m settlement with Sanofi over the termination of their alliance, which focused on the development and commercialisation of diabetes drug Zynquista (sotagliflozin).
Flexion Therapeutics licences pain therapy from Xenon
US-based Flexion Therapeutics has signed an agreement with Canadian Xenon Pharmaceuticals to acquire worldwide rights for the development and commercialisation of a NaV1.7 inhibitor, XEN402, to treat post-operative pain.
Genmab partners Tempus to identify new cancer targets
Danish biotechnology company Genmab has partnered with US-based technology firm Tempus to research and develop disease targets in oncology.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.